Drug Profile


Alternative Names: GLS4; Morphothiadin; Morphothiadine mesilate; Morphothiadine mesylate

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HEC Pharm
  • Class Antivirals; Mesylates
  • Mechanism of Action Hepatitis B virus replication inhibitors; Viral core protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Hepatitis B

Most Recent Events

  • 20 Oct 2017 Interim pharmacodynamics data from preclinical study in Hepatitis B presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 25 Aug 2016 Phase-II/III clinical trials in Hepatitis B in China (PO) (HEC Pharm pipeline, August 2016)
  • 11 Jan 2016 Phase-II development is ongoing in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top